Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 533 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: external beam radiation therapy Clear all
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

NCT03122509
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
durvalumab, tremelimumab, Radiotherapy (RT), ablation
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 2 Interventional

Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

NCT01591577
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma Multiforme
Interventions
Lapatinib/Temozolomide/radiation
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 9, 2026, 9:31 AM EDT
Not listed Phase 2 Interventional

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

NCT00436267
View directory record Official record
Conditions
Metastatic Cancer, Pancreatic Cancer
Interventions
fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 9, 2026, 9:31 AM EDT
Recruiting Not applicable Interventional

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

NCT05197881
View directory record Official record
Conditions
Cervical Cancer by FIGO Stage 2018
Interventions
Varian Ethos Adaptive Radiation Therapy
Device
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
5
States / cities
Burmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 9, 2026, 9:31 AM EDT
Not listed Not applicable Interventional

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT00079365
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer

NCT00012012
View directory record Official record
Conditions
Cervical Cancer, Radiation Toxicity
Interventions
Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy, External beam radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
17
States / cities
Jacksonville, Florida • Jacksonville Beach, Florida • Jascksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 9, 2026, 9:31 AM EDT
Withdrawn Not applicable Interventional

Proton Therapy for High Risk Prostate Cancer

NCT01811810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy (XRT), Androgen Deprivation Therapy (ADT), Chemotherapy
Radiation · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
499
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 353 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

NCT00225420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 9, 2026, 9:31 AM EDT
Terminated No phase listed Observational

Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy

NCT04927559
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme

NCT01752491
View directory record Official record
Conditions
Glioblastoma, GBM, Glioblastoma Multiforme
Interventions
Ascorbate, Temozolomide, Radiation therapy
Drug · Radiation
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 9, 2026, 9:31 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

NCT05100472
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Not applicable Interventional

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

NCT03418792
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy
Interventions
Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 9, 2026, 9:31 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 9, 2026, 9:31 AM EDT
Active, not recruiting Phase 3 Interventional

Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)

NCT04365374
View directory record Official record
Conditions
Brain Metastases
Interventions
Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
Device · Radiation
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 9, 2026, 9:31 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8
Interventions
Durvalumab, External Beam Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 9, 2026, 9:31 AM EDT
Not listed Phase 1 Interventional

Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00006212
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, vinblastine sulfate, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
Center for Molecular Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Radiation Therapy Using 3-Dimensional Treatment Planning in Patients With Non-small Cell Lung Cancer

NCT00002484
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 9, 2026, 9:31 AM EDT
Active, not recruiting Phase 1 Interventional Results available

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

NCT04900792
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy, Temozolomide
Drug · Radiation
Lead sponsor
Bryan Allen
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 9, 2026, 9:31 AM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 9, 2026, 9:31 AM EDT
Completed Phase 3 Interventional

Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer

NCT00241384
View directory record Official record
Conditions
Prostate Cancer
Interventions
External beam radiation, Pd-103
Procedure
Lead sponsor
Schiffler Cancer Center
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Wheeling, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 9, 2026, 9:31 AM EDT
Not yet recruiting Phase 2 Interventional

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517
View directory record Official record
Conditions
High-Risk Localized Prostate Cancer
Interventions
EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 9:31 AM EDT